Press release
Emesis (Anti-Emetic) Market is projected to reach USD 11.92 billion by 2034
Emesis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71135
The emesis pathway involves a complex interaction between the gastrointestinal tract, vestibular system, chemoreceptor trigger zone (CTZ), and central vomiting center. Anti-emetic drugs-including 5-HT3 antagonists, NK1 receptor antagonists, dopamine antagonists, and antihistamines-are critical in improving patient comfort, treatment adherence (especially during cancer therapy), and overall quality of life.
Key Market Highlights
• 2024 Market Size: USD 7.46 billion
• 2034 Forecast: USD 11.92 billion
• CAGR (2025-2034): 4.9%
• Largest Segment: Chemotherapy-induced nausea and vomiting (CINV)
• Fastest-Growing Segment: Neurokinin-1 (NK1) receptor antagonists
Epidemiology & Clinical Insights
1. High Burden of Chemotherapy-Induced Nausea and Vomiting (CINV)
• Affects up to 80% of patients receiving chemotherapy.
• Strongest market segment due to repeated dosing and guideline-driven prescribing.
2. Postoperative Nausea and Vomiting (PONV)
• Occurs in ~30-50% of surgical procedures.
• Prevention protocols increasing anti-emetic adoption.
3. Gastrointestinal & Vestibular Conditions
Includes:
• Gastroenteritis
• Migraine-associated emesis
• Motion sickness
• Inner ear disorders
4. Pregnancy-Related Nausea
Affects up to 70-80% of pregnant women, with severe hyperemesis gravidarum requiring medical management.
Market Growth Drivers
1. Increasing Cancer Incidence and Chemotherapy Use
CINV remains the largest clinical use-case for anti-emetics globally.
2. Introduction of Novel Multi-Receptor Targeting Agents
Combination therapies that block serotonin, dopamine, and NK1 pathways improve suppression of acute and delayed emesis.
3. Expansion of Surgical Procedures Worldwide
Higher PONV risk drives demand for prophylactic anti-emetics.
4. Growing Awareness & Clinical Guidelines
ASCO, MASCC, and NCCN guidelines influence standardized anti-emetic use.
5. Advances in Drug Delivery Technologies
Examples include:
• Transdermal patches
• Oral disintegrating tablets
• Long-acting injectable formulations
Market Restraints
• Side effects (sedation, constipation, headache)
• High cost of NK1 antagonists and combination regimens
• Limited efficacy in some refractory cases
• Safety concerns in pregnancy and pediatrics for certain drug classes
Market Opportunities
1. Long-Acting & Sustained-Release Delivery Systems
Useful for chronic conditions and multi-day chemotherapy cycles.
2.Based Therapeutics
Emerging clinical interest for treatment-resistant nausea.
3. Personalized Treatment Approaches
Genetic polymorphism-based prediction of anti-emetic response.
4. AI-Driven Predictive Models
Forecasting emesis episodes for optimized prophylactic therapy.
5. Pediatric Formulations
Growing demand for child-friendly dosage forms.
Segmentation Overview
By Drug Class
• 5-HT3 receptor antagonists (ondansetron, granisetron, palonosetron)
• NK1 receptor antagonists (aprepitant, fosaprepitant, rolapitant)
• Dopamine antagonists (metoclopramide, prochlorperazine)
• Antihistamines
• Others (benzodiazepines, steroids as adjuncts)
By Indication
• Chemotherapy-induced nausea and vomiting (CINV)
• Postoperative nausea and vomiting (PONV)
• Motion sickness
• Gastrointestinal disorders
• Pregnancy-related emesis
• Vertigo and vestibular disorders
By Route of Administration
• Oral
• Injectable
• Transdermal
• Sublingual/oral disintegrating
By End User
• Hospitals
• Oncology centers
• Ambulatory surgical centers
• Clinics
• Retail & online pharmacies
Explore Full Report here: https://exactitudeconsultancy.com/reports/71135/emesis-market
Regional Insights
North America - Largest Market
High cancer prevalence, advanced surgical care, and strong uptake of NK1 inhibitors.
Europe - Growing Adoption of Combination Anti-Emetic Regimens
Standardized treatment guidelines and expanded access to specialty oncology care.
Asia Pacific - Fastest Growing
Rising chemotherapy utilization, large surgical volume, and increasing awareness of PONV management.
Latin America - Emerging
Improved access to oncology and gastroenterology treatment pathways.
Middle East & Africa - Developing
Gradual adoption of modern anti-emetic therapies.
Competitive Landscape
Leading companies shaping the anti-emetic landscape include:
• Merck & Co.
• Roche
• Takeda
• Novartis
• Pfizer
• Teva Pharmaceuticals
• GlaxoSmithKline
• Cipla
• Dr. Reddy's Laboratories
• Eisai Co.
Key focus areas include multi-receptor targeting drugs, long-acting dosage forms, and combination therapies.
Recent Market Developments
• New approvals for long-acting NK1-5HT3 combination agents
• Emerging based formulations for refractory nausea
• Expansion of palonosetron-based multi-day emesis control
• AI-enabled monitoring tools for predicting chemotherapy-related nausea
• Rise in generic availability of leading anti-emetics
Future Outlook (2025-2034)
The Emesis Market is expected to expand steadily as:
• Cancer incidence increases globally
• Advanced surgical care expands, raising PONV management needs
• Novel multi-pathway agents improve patient outcomes
• Personalized anti-emetic strategies gain traction
• Digital monitoring tools support proactive therapy
By 2034, the market is projected to reach USD 11.92 billion, driven by growth in oncology, surgery, gastroenterology, and emergency care.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71135/emesis-market
Our More Reports:
Soft Mist Inhalers (SMIs) Market
https://exactitudeconsultancy.com/reports/45068/soft-mist-inhalers-smis-market
Chronic Disease Management Market
https://exactitudeconsultancy.com/reports/47415/chronic-disease-management-market
Health Insurance Market
https://exactitudeconsultancy.com/reports/47847/health-insurance-market
Long-Term Care Market
https://exactitudeconsultancy.com/reports/47917/long-term-care-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emesis (Anti-Emetic) Market is projected to reach USD 11.92 billion by 2034 here
News-ID: 4310983 • Views: …
More Releases from Exactitude Consultancy
Generalized Myasthenia Gravis (gMG) Market was valued at USD 2.4 billion in 2024 …
Generalized Myasthenia Gravis (gMG) Market Overview
The Generalized Myasthenia Gravis (gMG) market was valued at USD 2.4 billion in 2024 and is projected to reach USD 6.1 billion by 2034, growing at a CAGR of around 9.8%. Growth is driven by the rapid adoption of biologics, antibody-targeted therapies, and improved diagnostic awareness for autoimmune neuromuscular disorders.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72089
Key Market Drivers
• Rising global prevalence of autoimmune…
Chronic Plaque Psoriasis Market was valued at USD 24.5 billion in 2024 and is pr …
Chronic Plaque Psoriasis Market Overview
The Chronic Plaque Psoriasis Market was valued at USD 24.5 billion in 2024 and is projected to reach USD 43.8 billion by 2034, growing at a CAGR of around 6.2%. Growth is fueled by rising disease prevalence, strong uptake of biologics, and continuous expansion of dermatology specialty care.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71377
Key Market Drivers
• Increasing global prevalence of moderate to severe plaque psoriasis.
• Rapid…
Chronic Liver Disease Market is projected to reach USD 22.31 billion by 2034
The global Chronic Liver Disease (CLD) Market was valued at USD 12.84 billion in 2024 and is projected to reach USD 22.31 billion by 2034, growing at a CAGR of 5.9% from 2025 to 2034. Growth is fueled by increasing global prevalence of liver fibrosis, cirrhosis, viral hepatitis, autoimmune liver diseases, alcohol-related liver disease (ARLD), and metabolic-associated steatotic liver disease (MASLD/MASH). Advances in diagnostic imaging, biomarker-based screening, antifibrotic drug development,…
Birch Allergy Market was valued at USD 1.45 billion in 2024 and is projected to …
The Birch Allergy Market was valued at USD 1.45 billion in 2024 and is projected to reach ~USD 2.62 billion by 2034, growing at a CAGR of around 6.1%. Rising prevalence of seasonal allergies, improved diagnostic awareness, and the increasing use of immunotherapy are the primary factors fueling market growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71309
Key Market Drivers
• Higher incidence of birch pollen allergies in North America and Europe.
• Growing…
More Releases for NK1
CINV Treatment Market to Reach USD 3.9 Billion by 2034
Pune, India, November 11, 2025 - The global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market is projected to grow from USD 2.6 billion in 2024 to USD 3.9 billion by 2034, registering a CAGR of 4.1 %, according to Exactitude Consultancy. Rising cancer incidence, increasing chemotherapy adoption, and development of next-generation serotonin (5-HT3) and neurokinin-1 (NK1) receptor antagonists are driving global market expansion.
Download Full PDF Sample Copy of Market Report…
Chemotherapy-Induced Nausea and Vomiting (CINV) Market to Reach USD 4.02 Billion …
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing side effects of cancer treatment, significantly impacting patient quality of life and treatment adherence. Over the past decade, advances in anti-emetic drugs, combination therapies, and personalized medicine have improved patient outcomes, but unmet needs persist in managing acute, delayed, and breakthrough CINV.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72895
Growing global cancer prevalence, increasing adoption of highly emetogenic…
Emesis Market to Reach USD 10.4 Billion by 2034
Emesis, commonly referred to as vomiting, is a protective reflex triggered by the central nervous system to expel harmful substances from the stomach. While a natural response, emesis becomes a clinical concern when it occurs due to conditions such as chemotherapy-induced nausea and vomiting (CINV), pregnancy-related nausea, post-operative recovery, gastroenteritis, and motion sickness. Its impact on patient comfort, treatment compliance, and recovery rates makes effective emesis management a cornerstone of…
Postoperative Nausea and Vomiting Market Size And Global Industry Forecast 2034
Introduction
Postoperative nausea and vomiting (PONV) are among the most common and unpleasant side effects following surgery. Affecting a significant proportion of patients, PONV can lead to discomfort, delayed recovery, and extended hospital stays, further increasing healthcare costs. While the occurrence of nausea and vomiting after surgery is often considered a short-term complication, its impact on patient well-being is substantial. The condition is influenced by various factors, including the type of…
Global Antiemetics Market to Reach USD 11.20 B by 2030 at ~6% CAGR
◉ Global Antiemetics Market Forecast to Reach USD 11.20 B by 2030, Expanding at ~6.0% CAGR
According to a recent Grand View Research report, the global Antiemetics drugs market-used primarily for nausea and vomiting-is projected to grow from approximately USD 7.90 billion in 2024 to around USD 11.20 billion by 2030, representing a CAGR of about 5.98% over the forecast period .
Download your sample copy of this report today!https://www.maximizemarketresearch.com/request-sample/126745/…
Market Status and Future Forecast 2015-2024 on Global Chemotherapy-Induced Nause …
Global Chemotherapy-Induced Nausea and Vomiting Drugs market research report covers the overview, summary, market dynamics, competitive analysis, and leading player's various strategies to sustain in the global market. The Chemotherapy-Induced Nausea and Vomiting Drugs report covers the five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the Chemotherapy-Induced Nausea and Vomiting…
